Blogs Detail
Views: 4732 Author: yourxc Publish Time: 2026-11-05 Origin: Site
Search for the best skin whitening injection and you will usually meet the same three names: glutathione, vitamin C (ascorbic acid) and tranexamic acid (TXA). Clinics often present them as interchangeable "brightening shots", yet they work through different pathways, are delivered in different ways and carry very different levels of evidence. So which brightens skin best? The honest answer depends on the pigment problem being treated.
In this article, "brightening" means evening out tone and fading excess pigment such as melasma, sun spots or post-inflammatory marks. It does not mean changing a person's natural, genetically determined skin color, and none of these ingredients can do that permanently. Below you will find a side-by-side comparison table, a short profile of each ingredient, a decision guide by skin concern and the key safety and regulatory points that clinics and distributors should know.
Factor | Glutathione (GSH) | Vitamin C (ascorbic acid) | Tranexamic acid (TXA) |
|---|---|---|---|
Main mechanism | Antioxidant tripeptide; inhibits tyrosinase directly and indirectly and shifts melanin production from dark eumelanin toward lighter phaeomelanin | Antioxidant; inhibits tyrosinase by interacting with copper at the enzyme's active site, reducing melanin formation | Plasmin inhibitor; interrupts the plasminogen–plasmin pathway that links UV exposure and skin cells to melanocyte stimulation |
How it is used | Oral capsules or lozenges, topical creams; IV drips are popular but off-label; sometimes added to intradermal mesotherapy cocktails | Topical serums; intradermal mesotherapy or microneedling for pigment; high-dose IV infusions are a separate, systemic use | Intradermal microinjection or mesotherapy into the lesion, microneedling, topical, and oral (prescription) |
Best suited to | Generalized dullness and antioxidant support, as an add-on | Dullness, photo-damage and mild epidermal pigment; a common partner to TXA | Melasma and stubborn, hormone- or UV-driven facial pigment |
Evidence quality | Small oral and topical RCTs show modest melanin-index reductions; only one weak placebo-controlled IV study, which was not significant | Small trials and a 2024 meta-analysis show mesotherapy with vitamin C performs similarly to TXA mesotherapy in melasma | The strongest of the three for melasma, though most injection studies are still small and short |
Key safety notes | IV use linked to liver, kidney and skin reactions in regulator warnings; no approved IV dosing for skin lightening | Intradermal use can sting or burn; high-dose IV use carries kidney-stone and G6PD-deficiency concerns | Local redness, bruising and discomfort; screening for clotting risk is standard practice before systemic use |
Typical combinations | Added to TXA + vitamin C cocktails | Paired with TXA, with or without glutathione | Base ingredient of most melasma cocktails |
Glutathione is a natural antioxidant found inside almost every cell. Reviews describe its lightening effect as coming from direct and indirect inhibition of tyrosinase and from switching melanin synthesis toward lighter pigment (Sonthalia et al., 2016). In controlled studies, however, the effect is modest. A randomized, double-blind trial in 60 Thai volunteers found that 500 mg of oral glutathione daily for four weeks reduced melanin indices more than placebo at only two of six sites (Arjinpathana and Asawanonda). An open-label study of a buccal lozenge in 30 Filipino women also reported falling melanin indices, but it had no placebo group (Handog et al., 2016).
The evidence for intravenous glutathione is weaker still. The only placebo-controlled IV study found no significant difference from saline (37.5% vs 18.7% improved, p = 0.054), the improvement faded within six months, and several participants had abnormal liver tests or anaphylaxis (Zubair et al., 2016). A 2024 systematic review concluded that IV glutathione is contraindicated for skin lightening and that glutathione "may work more as an antioxidant in melasma" (Sarkar et al.). For patient-friendly background, see our guide to how glutathione skin whitening injections work.
Ascorbic acid neutralizes free radicals generated by UV light and inhibits tyrosinase, which is why it has long been used for photo-ageing and hyperpigmentation (Telang, 2013). Its main weakness is delivery: vitamin C is unstable and hard to get into the dermis at useful concentrations, which explains the interest in mesotherapy and microneedling.
When vitamin C is injected intradermally for melasma, it holds its own. A 2024 meta-analysis of five studies (127 patients) found no statistically significant difference in MASI improvement between TXA mesotherapy and vitamin C mesotherapy and judged both to be safe (Liao et al.). The studies were small, so this is best read as "comparable within limited data" rather than proof of equivalence.
Tranexamic acid was developed as a medicine to reduce bleeding. Its role in pigment comes from blocking plasmin activity, a pathway involved in UV-triggered melanocyte activation. In the first intradermal study, 85 Korean women received weekly 4 mg/mL microinjections into melasma lesions for 12 weeks; the mean MASI score fell from 13.22 to 7.57 with minimal side effects (Lee et al., 2006). That study had no control group. A later randomized trial in 60 patients found 35.72% MASI improvement with TXA microinjections and 44.41% with TXA delivered by microneedling, with no major adverse events (Budamakuntla et al., 2013).
Protocol details, session intervals and patient selection are covered in our dedicated article on tranexamic acid mesotherapy for melasma, so we will not repeat them here.
There is no single best whitening injection. The right choice follows the diagnosis:
TXA is the first ingredient most dermatologists reach for, delivered intradermally or with microneedling, alongside strict sun protection. Vitamin C mesotherapy is a reasonable alternative or partner, given the comparable results in the meta-analysis. Glutathione is an optional add-on, not a stand-alone answer.
For tired, sallow or photo-damaged skin without a defined pigment disorder, antioxidant support matters most. Vitamin C is the logical core, and glutathione may contribute antioxidant benefit. Expectations should be framed as "fresher, more even skin", not a lighter complexion.
Marks left after acne or irritation usually fade with time, sun protection and gentle topical care. If injectables are used, low-irritation protocols with vitamin C or TXA make sense, because aggressive treatment can trigger new pigment. Our overview of skin brightening injectables for hyperpigmentation explains the main pigment types in more detail.
Vitamin C and glutathione are often chosen as supportive ingredients around lasers or peels. They do not replace a pigment-specific treatment plan.
Because the three ingredients act on different steps of pigment formation, modern brightening formulas often combine TXA, vitamin C and glutathione rather than choosing one. Clinical data support this logic, at least in small trials. In a double-blind, split-face trial of 24 melasma patients, TXA plus ascorbic acid lowered MASI scores more than TXA plus placebo at weeks 8 and 12, although burning pain was more noticeable on the combination side (Pazyar et al., 2022). In another split-face trial of 30 patients, a cocktail of TXA 4 mg/mL, vitamin C 3% and glutathione 2% reduced mMASI more than TXA and vitamin C alone, with similar rates of redness, swelling and bruising (Iraji et al., 2019).
For a broader introduction to how these products are positioned, read our guide to whitening injections and skin brightening.
IV glutathione is not an approved skin-whitening drug in many markets. In its 2019 advisory, the Philippine FDA stated it had not approved any injectable product for skin lightening, approved injectable glutathione only as an adjunct in cisplatin chemotherapy, and warned of possible liver, kidney and nervous-system effects and Stevens-Johnson syndrome.
High-dose IV vitamin C carries its own risks. The same advisory noted that vitamin C injections may form kidney stones and that large doses have led to hemodialysis in people with G6PD deficiency.
Local injections are not risk-free. Expect transient redness, stinging, swelling or bruising. Sterile technique and correct depth are essential.
Results are not permanent. Pigment returns if UV exposure, hormones or inflammation persist. Daily broad-spectrum sun protection is part of every protocol.
Know your local rules. Product registration and who may inject differ by country. Treatment should be prescribed and given by qualified practitioners.
Clinics see better outcomes and fewer complaints when they diagnose the pigment type first, choose TXA-based protocols for melasma and present glutathione honestly as an antioxidant adjunct rather than a skin-color changer. Distributors should check that every product's registration and labeling fit their target market.
AOMA manufactures brightening mesotherapy solutions, including TXA, vitamin C and combination formulas, for stock supply and OEM. You can browse the AOMA skin whitening injection range. The MOQ starts from 200 units for both stock and OEM orders. Stock orders ship within 24 hours, and OEM lead time is 2–3 weeks after artwork, formula and packaging details are confirmed. AOMA holds CE, ISO 13485, GMP and FDA certificates.
There is no single winner. For melasma, tranexamic acid has the most supportive injection data. For general dullness, vitamin C is a sensible antioxidant choice. Glutathione is mainly an add-on. A practitioner should diagnose the pigment problem before choosing.
Not clearly. Both have only modest, short-term evidence. Vitamin C has more injection data for melasma, while IV glutathione has failed to beat placebo in its only controlled trial.
Yes, combination cocktails are common, and small split-face trials found that adding vitamin C, and then glutathione, to TXA improved melasma scores. Burning or stinging may increase with the combination.
No. They can fade excess pigment and even out tone, but they do not change natural skin color, and results fade without sun protection and maintenance.
Regulators such as the Philippine FDA have warned against it, and a 2024 systematic review considered IV glutathione contraindicated for skin lightening because of a lack of efficacy and side effects.
Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626–631. PMID: 16706756.
Budamakuntla L, Loganathan E, Suresh DH, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139–143. PMID: 24163529.
Liao X, Cheng F, Jiang Y. Efficacy and safety of mesotherapy with tranexamic acid versus vitamin C in the treatment of melasma: a meta-analysis and systemic review. J Cosmet Dermatol. 2024;23(9):2785–2792. PMID: 38693699.
Pazyar N, Molavi SN, Hosseinpour P, et al. Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: a split-face comparative trial. Health Sci Rep. 2022;5(2):e537. PMID: 35284654.
Iraji F, Nasimi M, Asilian A, et al. Efficacy of mesotherapy with tranexamic acid and ascorbic acid with and without glutathione in treatment of melasma: a split face comparative trial. J Cosmet Dermatol. 2019;18(5):1416–1421. PMID: 30735611.
Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82(3):262–272. PMID: 27088927.
Sarkar R, Yadav V, Yadav T, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025;64(6):992–1004 (online 2024). PMID: 39444151.
Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97–102. PMID: 20524875.
Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Int J Dermatol. 2016;55(2):153–157. PMID: 26148180.
Zubair S, Hafeez S, Mujtaba G. Efficacy of intravenous glutathione vs. placebo for skin tone lightening. J Pak Assoc Dermatol. 2016;26(3):177. https://jpad.com.pk/index.php/jpad/article/view/18
Telang PS. Vitamin C in dermatology. Indian Dermatol Online J. 2013;4(2):143–146. PMID: 23741676.
Food and Drug Administration Philippines. FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent. 2019. https://www.fda.gov.ph/fda-advisory-no-2019-182-unsafe-use-of-glutathione-as-skin-lightening-agent/
This article is for educational purposes only and is not medical advice. Injectable brightening treatments should be assessed and performed by qualified practitioners in line with local regulations.
Laboratory
Product Category
Blogs